A practical approach to caring for atopic dermatitis in children DOI
Diana K. Bayer

Current Opinion in Pediatrics, Journal Year: 2023, Volume and Issue: 35(6), P. 686 - 691

Published: Sept. 29, 2023

Purpose of review Atopic dermatitis is a chronic, systemic disease with primary cutaneous clinical manifestations and commonly attributed to an exaggerated Th2 inflammatory response. Recent research regarding risk factors, prevention, features, management atopic will be reviewed. findings In the last decade, advances have been made in identifying factors that either confer increased for or protection from associated atopy. Progress has also this disease. Promising biomarkers therapeutically informative characteristics identified young children without presence eczema, but much yet elucidated. clarifying advantages disadvantages respective medical managements, including not limited topical corticosteroids, calcineurin inhibitors, phototherapy, immunosuppressants, targeted immunotherapy. Given may show variable efficacy child, optimized skin care regimen utmost importance as well. Summary challenging, chronic incurs significant morbidity affected children. Although options somewhat disappointing years past, promising results observed recent

Language: Английский

Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis DOI Creative Commons
Amy S. Paller, Elaine C. Siegfried, Michael J. Cork

et al.

Pediatric Drugs, Journal Year: 2024, Volume and Issue: 26(2), P. 163 - 173

Published: Jan. 24, 2024

Patients with atopic dermatitis (AD), particularly infants and young children, are at greater risk of developing skin infections. In this study, we assessed infection rates in AD patients aged 6 months to 5 years treated dupilumab.

Language: Английский

Citations

6
Therapeutic effectiveness of upadacitinib on individual types of rash in Japanese patients with moderate‐to‐severe atopic dermatitis DOI Open Access
Teppei Hagino,

Mai Yoshida,

Risa Hamada

et al.

The Journal of Dermatology, Journal Year: 2023, Volume and Issue: 50(12), P. 1576 - 1584

Published: Sept. 4, 2023

Atopic dermatitis (AD) is a chronic eczematous disease with various types of rash, erythema, edema/papulation, excoriation, or lichenification. Janus kinase 1 inhibitor upadacitinib effective for moderate-to-severe AD. We aimed to investigate the therapeutic effects on each rash type in AD patients real-world clinical practice. Seventy-two Japanese were treated oral 15 mg/day plus topical corticosteroids. The Eczema Area and Severity Index (EASI) scores lichenification whole body head neck, upper limbs, lower trunk assessed at weeks 0, 4, 12 treatment. proportions who achieved resolution least 75% reduction EASI from baseline (EASI 75) individual calculated 4 anatomical site. rates 38.3%, 23.7%, 21.7%, 8.3% week 18.3%, 18.6%, 11.6%, 13.3% 12, respectively. all significantly decreased compared 0. achievement 75 67.2%, 66.7%, 49.2%, 37.7% 57.3%, 65%, 41%, 41% rate erythema neck (45.3%) was than that limbs (71%) (70.8%), (42.2%) (69.2%). These results indicate types, especially excoriation while head-and-neck might be less responsive upadacitinib.

Language: Английский

Citations

15
Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan DOI Creative Commons
Teppei Hagino,

Mai Yoshida,

Risa Hamada

et al.

Journal of Dermatological Treatment, Journal Year: 2023, Volume and Issue: 34(1)

Published: Dec. 10, 2023

Background Atopic dermatitis (AD) is a chronic eczematous disease with severe pruritus. Janus kinase (JAK) inhibitors, upadacitinib, baricitinib, and abrocitinib, are systemic treatments for AD. The outcomes of switching from one JAK inhibitor to another have not been examined.

Language: Английский

Citations

14
Longitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients treated with dupilumab DOI
Elena Goleva, Evgeny Berdyshev, Simion Kreimer

et al.

Journal of Allergy and Clinical Immunology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
Early-life protein-bound skin ceramides help predict the development of atopic dermatitis DOI Creative Commons
Chia‐Lun Chang, Evgeny Berdyshev, Elasma Milanzi

et al.

Journal of Allergy and Clinical Immunology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Skin lipids are crucial components of the skin barrier. Individuals with atopic dermatitis (AD or eczema) have a different lipid profile from those without. However, whether altered precede and predict subsequent risk AD remained unclear, especially for phenotypes. We sought to examine relationship between phenotypes in infants. forearms 133 infants family history allergic disease were sampled using tape strips at age 6 weeks. Lipids quantified liquid chromatography-tandem mass spectrometry. by 1 year was diagnosed modified UK Working Party Criteria. Allergic sensitization assessed prick tests. Associations predictive discrimination estimated univariable logistic regression. Potential causation explored multivariable Reduced levels protein-bound ω-hydroxyl sphingosine (POS) ceramides C30 C32 fatty acids weeks associated increased year. In univariate models, number POS predicted AD, such as PO30:0-C20S (area under curve, 0.65; 95% CI, 0.55-0.75). After confounders adjusted, only (adjusted odds ratio, 0.62; 0.39-0.96 per 1-SD increase), trend without 0.57; 0.31-1.05) but not 0.76; 0.39-1.47). development nonatopic suggesting that these may play role pathogenesis be useful biomarkers. Interventions increase reduce incidence AD.

Language: Английский

Citations

0
Dupilumab successfully controlled eczema in Wiskott-Aldrich Syndrome over 52 weeks DOI
Changhua Zhu, Yaxuan Zheng, Lianming Liao

et al.

Pediatric Research, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 24, 2025

Language: Английский

Citations

0
Systemic barrier dysfunction in type 2 inflammation diseases: perspective in the skin, airways, and gastrointestinal tract DOI Creative Commons
Juan Meng, Hao Xiao, Feng Xu

et al.

Immunologic Research, Journal Year: 2025, Volume and Issue: 73(1)

Published: March 11, 2025

The epithelial barrier in different organs is the first line of defense against environmental insults and allergens, with type 2 immunity serving as a protective function. Genetic factors, biological chemical from surrounding environment altered regulate homeostasis through disruption tight junction proteins or dilated intercellular spaces. Recent studies suggest that dysfunction contributes to pathologic alteration diseases immune dysregulation including (but not limited to) atopic dermatitis, prurigo nodularis, asthma, chronic rhinosinusitis nasal polyps, eosinophilic esophagitis. In this review, we summarized current understanding its interaction inflammation across organs, discussed role pathogenesis inflammation. addition, recent progresses emerging restorative therapies are reviewed.

Language: Английский

Citations

0
Bleach baths enhance skin barrier, reduce itch but do not normalize skin dysbiosis in atopic dermatitis DOI Creative Commons
Ania Stolarczyk, Nelissa Pérez-Nazario, Sara A. Knowlden

et al.

Archives of Dermatological Research, Journal Year: 2023, Volume and Issue: 315(10), P. 2883 - 2892

Published: Sept. 27, 2023

Abstract Studies have demonstrated that bleach baths improve atopic dermatitis (AD) severity; however, the effects on itch, skin barrier, and cutaneous microbial composition are less clear. We examined whether reduce normalize barrier function, S. aureus absolute abundance, increase diversity in adults with AD who were colonized their non-lesional skin. This was an open label, non-randomized, controlled trial performed at a single academic center. Fifteen five non-atopic healthy controls (NA) instructed to take two (0.005% NaClO; 5–10 min duration) per week for total of 12 weeks as add-on therapy. Adults 18 65 years (inclusive) mild severe recruited EASI score > 6.0, culture positivity, access bathtub, ability willingness maintain current topical or systemic treatments. They evaluated baseline (before baths), 6 weeks, after intervention twice-weekly baths. Efficacy measurements included well 5-D Pruritus ItchyQoL™. Transepidermal water loss (TEWL) stratum corneum (SC) integrity assay assess barrier. Skin dysbiosis measured by cultivation, abundance (qPCR thermonuclease gene), V1-V3 16S rRNA gene sequencing lesional After baths, 8/15 (53.3%) subjects achieved 50 significant reduction itch pruritus Itchy QoL. Eighty-seven percent reported improvements sleep quality. At study entry, had higher TEWL values than NA subjects, only experienced ( p = 0.006). Similarly, SC improved early subjects. Notably, no effect culture-positivity, qPCR diversity. The addition improves investigator-assessed severity, patient-reported physiological measures function adult while having qualitative quantitative . Trial Registration : ClinicalTrials.gov Identifier: NCT01996150, Date registration: November 27th, 2013.

Language: Английский

Citations

9
Proteomic alterations in patients with atopic dermatitis DOI

Ashley Obi,

Camille Rothenberg‐Lausell,

Sophia Levit

et al.

Expert Review of Proteomics, Journal Year: 2024, Volume and Issue: 21(5-6), P. 247 - 257

Published: May 16, 2024

Atopic Dermatitis (AD) is the most common inflammatory skin disease with a complex and multifactorial pathogenesis. The use of proteomics in understanding AD has yielded discovery novel biomarkers may further expand therapeutic options.

Language: Английский

Citations

1
TMT-proteomics reveals the therapeutic effects of Lianling decoction against atopic dermatitis through Staphylococcus aureus infection DOI Creative Commons

Lili Zhang,

Ziyi Fan, Lin Li

et al.

Heliyon, Journal Year: 2024, Volume and Issue: 10(19), P. e38381 - e38381

Published: Sept. 26, 2024

Language: Английский

Citations

0